Regulatory · source year

2026 regulatory records

89 selected, source-linked regulatory records dated 2026. This is selective source coverage, not a complete timeline.

Dated records

89 selected records.

Peptide profiles

39 connected profiles.

Cited sources

96 distinct public records.

Cited chronology

Dated source records

All record types in 2026 →

November 2026

2 records

Exenatide

Federal Register notice 2026-23141

The Federal Register published notice 2026-23141, attributed to FDA and its parent HHS department, on 2026-11-13. Its official title is “Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

October 2026

4 records

September 2026

7 records

Lutetium Lu 177 dotatate

Drugs@FDA application ANDA217060

The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Lutetium Lu 177 dotatate

Drugs@FDA application NDA218525

The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

August 2026

7 records

Leuprolide + 1 more

Federal Register notice 2026-17222

The Federal Register published notice 2026-17222, attributed to FDA and its parent HHS department, on 2026-08-24. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Leuprolide and Octreotide.

Source: Federal Register via GovInfo ↗

→

Exenatide

Federal Register notice 2026-16998

The Federal Register published notice 2026-16998, attributed to FDA and its parent HHS department, on 2026-08-20. Its official title is “Advisory Committee; Endocrinologic and Metabolic Drugs Advisory Committee; Renewal,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

July 2026

11 records

Glucagon + 5 more

Federal Register notice 2026-15285

The Federal Register published notice 2026-15285, attributed to FDA and its parent HHS department, on 2026-07-29. Its official title is “Product-Specific Guidances; Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide, Teriparatide, Tirzepatide and Vosoritide.

Source: Federal Register via GovInfo ↗

→

Dalbavancin

Federal Register notice 2026-15149

The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

Source: Federal Register via GovInfo ↗

→

Vasopressin

Federal Register notice 2026-13492

The Federal Register published notice 2026-13492, attributed to FDA and its parent HHS department, on 2026-07-06. Its official title is “Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

June 2026

10 records

Liraglutide + 2 more

Federal Register notice 2026-12937

The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

Vasopressin

Federal Register notice 2026-11062

The Federal Register published notice 2026-11062, attributed to FDA and its parent HHS department, on 2026-06-03. Its official title is “Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Vasopressin.

Source: Federal Register via GovInfo ↗

→

May 2026

8 records

Palopegteriparatide

Federal Register notice 2026-10277

The Federal Register published notice 2026-10277, attributed to FDA and its parent HHS department, on 2026-05-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Palopegteriparatide.

Source: Federal Register via GovInfo ↗

→

Glucagon + 3 more

Federal Register notice 2026-08552

The Federal Register published notice 2026-08552, attributed to FDA and its parent HHS department, on 2026-05-01. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon, Liraglutide, Semaglutide and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

April 2026

9 records

Semaglutide

Federal Register notice 2026-08435

The Federal Register published notice 2026-08435, attributed to FDA and its parent HHS department, on 2026-04-30. Its official title is “Determination That OZEMPIC (Semaglutide) Solution, 2 Milligrams Per 1.5 Milliliters Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

Setmelanotide

Federal Register rule 2026-07863

The Federal Register published rule 2026-07863, attributed to FDA and its parent HHS department, on 2026-04-22. Its official title is “Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Setmelanotide Eligibility Gene Variant Detection System,” and PeptideScanner's exact reviewed identity mapping connects the document to Setmelanotide.

Source: Federal Register via GovInfo ↗

→

BPC-157 + 6 more

Federal Register notice 2026-07361

The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.

Source: Federal Register via GovInfo ↗

→

March 2026

10 records

Exenatide

Federal Register notice 2026-04546

The Federal Register published notice 2026-04546, attributed to FDA and its parent HHS department, on 2026-03-09. Its official title is “Aspen Global Inc. c/o Lachman Consultant Services, Inc., et al.; Withdrawal of Approval of 46 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

February 2026

15 records

Octreotide + 1 more

Federal Register notice 2026-03963

The Federal Register published notice 2026-03963, attributed to FDA and its parent HHS department, on 2026-02-27. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Octreotide and Semaglutide.

Source: Federal Register via GovInfo ↗

→

Semaglutide

Federal Register notice 2026-02786

The Federal Register published notice 2026-02786, attributed to FDA and its parent HHS department, on 2026-02-12. Its official title is “Jeremy Spencer Brown: Final Debarment Order,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

January 2026

6 records